Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim

Roche receives EU approval of Cotellic for use in combination with Zelboraf in advanced melanoma
- Details
- Category: Roche

AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
- Details
- Category: AstraZeneca

Bayer's new five-year-contraceptive submitted for EU and US marketing authorization
- Details
- Category: Bayer

Merck and Pfizer receive FDA Breakthrough Therapy designation for avelumab in metastatic Merkel cell carcinoma
- Details
- Category: Merck Group

Roche to restructure its manufacturing network for small molecules
- Details
- Category: Roche

Global partners announce donation of 500 millionth dose of azithromycin
- Details
- Category: Pfizer

More Pharma News ...
- International study prompts rethink on the rise of diabetes in cities
- Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years
- Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
- Pfizer expands its patient assistance program
- Merck recognized for digital workplace platform
- AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma
- Johnson & Johnson announces agreement to acquire Novira Therapeutics, Inc.